Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
Conditions: NSCLC; Melanoma; Kidney Cancer; Urothelial Carcinoma; Head and Neck Cancer Intervention: Other: Breathprint analysis and patient-reported outcomes Sponsors: University Health Network, Toronto; University of Amsterdam Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Melanoma | Non-Small Cell Lung Cancer | Research | Skin Cancer | Urology & Nephrology